Welcome to our dedicated page for Aehr Test Sys SEC filings (Ticker: AEHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aehr Test Systems filings document material events, operating results, capital actions and governance matters for a semiconductor test and burn-in equipment company. Recent Form 8-K disclosures include quarterly financial-result releases covering revenue, bookings, backlog, cash position and GAAP and non-GAAP earnings measures.
The filing record also includes capital-structure disclosures tied to an at-the-market common stock offering under a Form S-3 registration statement, along with proxy and annual meeting materials. Those governance filings address director elections, shareholder voting results, amendments to the company’s equity incentive and employee stock purchase plans, auditor ratification and executive-compensation matters.
AEHR TEST SYSTEMS director Howard T. Slayen sold 25,000 shares of Common Stock in an open-market transaction at $85.00 per share. After this sale, he directly holds 178,328 shares. The reported holdings include shares subject to unvested restricted stock units, which may vest over time under company equity award terms.
Aehr Test Systems director Laura Oliphant reported an open-market sale of 1,716 shares of Common Stock on April 16, 2026 at $81.54 per share. After this transaction, she directly held 16,716 shares, and this amount includes shares subject to unvested restricted stock units.
AEHR TEST SYSTEMS executive Vernon Rogers, Executive VP of Sales & Marketing, reported an open-market sale of company common stock. On April 16, 2026, he sold 5,000 shares at $86.88 per share. Following this transaction, he directly holds 161,633 shares, which include shares subject to unvested restricted stock units.
AEHR Test Systems VP Alistair N. Sporck sold shares in the company. On April 16, 2026, he executed an open-market sale of 2,000 shares of common stock at $81.8800 per share. After this sale, he directly holds 20,635 shares and indirectly holds 7,177 shares through a trust.
A footnote explains that the reported amounts include shares subject to unvested restricted stock units, meaning some of his reported holdings are still vesting and not yet fully unrestricted.
Rhea J Posedel reported sales of Common Stock. The filing lists three transactions: 02/13/2026 sale of 13,998 shares for $390,404.22, 04/09/2026 sale of 30,000 shares for $2,100,000.00, and 04/16/2026 sale of 15,000 shares for $1,210,743.00.
Charles Schwab Corporation submitted a Form 144 notice reporting a proposed sale of Common stock. The filing lists Restricted Stock Units of 470 and shares from an ESPP of 530 as covered securities. The form date shown is 04/17/2026 and the listing venue is NASDAQ.
AEHR Test Systems director Laura Oliphant reported an indirect sale of 4,665 shares of Common Stock at an average price of $85.5879 per share. The shares were held by a trust, and this transaction reduced that indirect position to zero shares. After the sale, she continues to hold 18,432 shares directly, which include shares subject to unvested restricted stock units.
AEHR TEST SYSTEMS director Rhea J. Posedel, through a trust, sold 15,000 shares of common stock in an open-market transaction at $80.72 per share.
After the sale, the trust holds 411,979 shares, including shares subject to unvested restricted stock units, and Posedel also holds 71,163 shares directly.
Rhea J Posedel filed a Form 144 seeking to sell 15,000 shares of Common Stock of AEHR through Oppenheimer & Co. The filing also reports sales in the past three months: 30,000 shares on 04/09/2026 for $2,100,000 and 13,998 shares on 02/13/2026 for $390,404.22.
Rhea J Posedel reported a proposed sale of 15,000 common shares under Rule 144. The filing lists prior sales of 13,998 shares on 02/13/2026 for $390,404.22 and 30,000 shares on 04/09/2026 for $2,100,000.